Literature DB >> 17464999

Increased activity of hepatic microsomal triglyceride transfer protein and bile acid synthesis in gallstone disease.

Juan Castro1, Ludwig Amigo, Juan Francisco Miquel, Cecilia Gälman, Fernando Crovari, Alejandro Raddatz, Silvana Zanlungo, Roberto Jalil, Mats Rudling, Flavio Nervi.   

Abstract

UNLABELLED: A strong interrelationship exists between the regulation of bile acid (BA) metabolism and hepatic very low density lipoprotein (VLDL) production. We have recently shown that BA synthesis is increased in gallstone disease. We investigated the activity of hepatic microsomal triglyceride transfer protein (MTTP) as a surrogate of VLDL production, BA synthesis, and mRNA expression levels of proteins that regulate fatty acid (FA) metabolism in the liver of gallstone (GS) patients compared with GS-free patients. Twenty-seven volunteers subjected to elective surgery; 9 were GS-free and 18 with GS agreed to have a liver biopsy. We quantified by a fluorescence assay the activity of MTTP and by quantitative reverse-transcription PCR (RT-PCR) the mRNA content of hepatic MTTP and genes that regulate hepatic sterol and FA metabolism. Plasma was assayed for lathosterol and 7alpha-hydroxy-4-cholesten-3-one. Liver histology was normal in GS and GS-free patients. Serum VLDL triglycerides and apoB were significantly increased in GS. Hepatic triglycerides tripled in GS (P<0.001) compared with GS-free. MTTP activity increased 70% (P<0.001). Serum lathosterol and hepatic cholesterol concentrations, and mRNA expressions of MTTP, CD36, and FABP1 were similar in GS-free and GS patients. Hepatic mRNA expression of hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR) and 3-hydroxyl-3-methyl-glutaryl-CoA synthase (HMGS) were significantly decreased--40% and 27%, respectively--in GS. Serum 7alpha-hydroxy-4-cholesten-3-one was 75% higher, and mRNA expression of CYP7A1 was increased sevenfold (P<0.001) in GS.
CONCLUSION: Hepatic MTTP activity and BA synthesis are increased in GS. Results suggest that hepatic VLDL production and trafficking of BA are increased in gallstone patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17464999     DOI: 10.1002/hep.21616

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  9 in total

1.  Gallstones and risk of cancers of the liver, biliary tract and pancreas: a prospective study within two U.S. cohorts.

Authors:  Xiao Luo; Wanshui Yang; Amit D Joshi; Kana Wu; Tracey G Simon; Chen Yuan; Lina Jin; Lu Long; Mi Na Kim; Chun-Han Lo; Xing Liu; Thomas A Abrams; Brian M Wolpin; Andrew T Chan; Edward L Giovannucci; Xuehong Zhang
Journal:  Br J Cancer       Date:  2022-06-17       Impact factor: 9.075

2.  Mutation screening of apical sodium-dependent bile acid transporter (SLC10A2): novel haplotype block including six newly identified variants linked to reduced expression.

Authors:  Olga Renner; Simone Harsch; Elke Schaeffeler; Matthias Schwab; Dietmar M Klass; Wolfgang Kratzer; Eduard F Stange
Journal:  Hum Genet       Date:  2009-01-30       Impact factor: 4.132

3.  Fecal bile acid excretion and messenger RNA expression levels of ileal transporters in high risk gallstone patients.

Authors:  Jorge Herrera; Ludwig Amigo; Constanze Husche; Carlos Benítez; Silvana Zanlungo; Dieter Lütjohann; Juan Francisco Miquel; Flavio Nervi
Journal:  Lipids Health Dis       Date:  2009-12-08       Impact factor: 3.876

4.  Decreased expression of cholesterol 7alpha-hydroxylase and altered bile acid metabolism in Apobec-1-/- mice lead to increased gallstone susceptibility.

Authors:  Yan Xie; Valerie Blanc; Thomas A Kerr; Susan Kennedy; Jianyang Luo; Elizabeth P Newberry; Nicholas O Davidson
Journal:  J Biol Chem       Date:  2009-04-22       Impact factor: 5.157

5.  Increased susceptibility to diet-induced gallstones in liver fatty acid binding protein knockout mice.

Authors:  Yan Xie; Elizabeth P Newberry; Susan M Kennedy; Jianyang Luo; Nicholas O Davidson
Journal:  J Lipid Res       Date:  2009-01-09       Impact factor: 5.922

6.  Hepatic Mttp deletion reverses gallstone susceptibility in L-Fabp knockout mice.

Authors:  Yan Xie; Ho Yee Joyce Fung; Elizabeth P Newberry; Susan Kennedy; Jianyang Luo; Rosanne M Crooke; Mark J Graham; Nicholas O Davidson
Journal:  J Lipid Res       Date:  2014-01-28       Impact factor: 5.922

7.  Ω-3 fatty acids prevent hepatic steatosis, independent of PPAR-α activity, in a murine model of parenteral nutrition-associated liver disease.

Authors:  Esther Prince; Farrah B Lazare; William R Treem; Jiliu Xu; Jahangir Iqbal; Xiaoyue Pan; Joby Josekutty; Meghan Walsh; Virginia Anderson; M Mahmood Hussain; Steven M Schwarz
Journal:  JPEN J Parenter Enteral Nutr       Date:  2013-06-11       Impact factor: 4.016

Review 8.  The blind men 'see' the elephant-the many faces of fatty liver disease.

Authors:  Madhusudana Girija Sanal
Journal:  World J Gastroenterol       Date:  2008-02-14       Impact factor: 5.742

9.  Bile acid metabolites in serum: intraindividual variation and associations with coronary heart disease, metabolic syndrome and diabetes mellitus.

Authors:  Carine Steiner; Alaa Othman; Christoph H Saely; Philipp Rein; Heinz Drexel; Arnold von Eckardstein; Katharina M Rentsch
Journal:  PLoS One       Date:  2011-11-14       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.